DuoCort Hosts Adrenal Insufficiency Symposium at the 10th European Congress of Endocrinology in Berlin
|| Print ||
|Monday, 14 April 2008 08:57 (UTC + 2)|
Prof emer Michael Besser will chair the symposium, which also features a number of other authorities in the field: Dr John Newell-Price, Prof Brian R Walker, and Dr Gudmundur Johannsson, Chief Medical Officer of DuoCort. The symposium will cover key aspects and recent developments in therapy for adrenal insufficiency, including choice of glucocorticoid and dosing, outcomes from current therapy, and ways to improve glucocorticoid replacement therapy.
DuoCort is developing a once-daily dual-release hydrocortisone tablet for adrenal insufficiency.
In December 2007, DuoCort completed the targeted enrolment in the pivotal phase II-III clinical trial evaluating 5 mg and 20 mg DuoCort™ dual-release hydrocortisone tablets for the treatment of adrenal insufficiency – the inability of the body to produce sufficient amounts of the essential hormone cortisol. The first data from the study is expected to be available in Q3 2008.
“Current research confirms that conventional therapy is suboptimal and is not serving these patients as well as it should. There is scope for improvement in the delivery of cortisol replacement and we are convinced DuoCort will deliver better long-term outcomes. This trial is a major step toward offering a better treatment option for patients with adrenal insufficiency”, commented Dr Johannsson.
For more information about DuoCort and its drug development programs, contact Greg Batcheller, CEO, tel. +46 46 288 5008. www.duocort.com
Notes to the editor
About adrenal insufficiency
About DuoCort AB